The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults

Sexually Transmitted Diseases

Volumn 32, Issue 11, 2005, Pages 703-709

  Cameron, Jennifer E ^a,c   Mercante, Donald ^a   O'Brien, Megan ^b,d   Gaffga, Ann M ^a   Leigh, Janet E ^a   Fidel Jr , Paul L ^a   Hagensee, Michael E ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; ASSAY; CAUCASIAN; COMPARATIVE STUDY; CONSENSUS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENOTYPE; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MOUTH INFECTION; POLYMERASE CHAIN REACTION; PREDICTION; PREVALENCE; RACE DIFFERENCE; RISK ASSESSMENT; SALIVA; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SALIVA; WARTS;

EID: 27944477713     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000175398.34610.2e     Document Type: Article

References (21)

1. Leigh J. Oral warts rise dramatically with use of new agents in HIV. HIV Clin 2000; 12:7.
2. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357:1411-1412.
3. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34:641-648.
4. Greenspan D, de Villiers EM, Greenspan JS, de Souza YG, zur HH. Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol 1988; 17:482-488.
5. Volter C, He Y, Delius H, et al. Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Int J Cancer 1996; 66:453-456.
6. Coutlee F, Trottier AM, Ghattas G, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis 1997; 24:23-31.
7. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004; 189:686-698.
8. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798-1805.
9. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36:3020-3027.
10. Lawton G, Thomas S, Schonrock J, Monsour F, Frazer I. Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. J Oral Pathol Med 1992; 21:265-269.
11. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363:1488-1489.
12. Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989; 115:621-625.
13. Palefsky JM, Silverman S Jr, Abdel-Salaam M, Daniels TE, Greenspan JS. Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med 1995; 24:193-197.
14. Mineta H, Ogino T, Amano HM, et al. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res 1998; 18:4765-4768.
15. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90:1626-1636.
16. Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human papillomavirus and risk of oral cancer. Laryngoscope 1998; 108:1098-1103.
17. Aggelopoulou EP, Skarlos D, Papadimitriou C, Kittas C, Troungos C. Human papilloma virus DNA detection in oral lesions in the Greek population. Anticancer Res 1999; 19:1391-1395.
18. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92:709-720.
19. Badaracco G, Venuti A, Morello R, Muller A, Marcante ML. Human papillomavirus in head and neck carcinomas: prevalence, physical status and relationship with clinical/pathological parameters. Anticancer Res 2000; 20:1301-1305.
20. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92:805-813.
21. Shin KH, Park KH, Hong HJ, et al. Prevalence of microsatellite instability, inactivation of mismatch repair genes, p53 mutation, and human papillomavirus infection in Korean oral cancer patients. Int J Oncol 2002; 21:297-302.